Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
April 28, 2020

Moderna seeks FDA approval for Phase II trial of Covid-19 vaccine

Moderna has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to conduct a Phase II clinical trial of its mRNA vaccine candidate, mRNA-1273, against Covid-19.

The study is expected to be supported by safety data from the ongoing Phase I study, which is led by the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).

Moderna said that the FDA provided initial feedback on the design of the Phase II study, which is set to launch in the second quarter of this year.

Read the full article here

Related Companies

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy